Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers innovative anti-CA9 products that target the highly selective carbonic anhydrase IX (CA9) enzyme, leveraging its unique expression profile in tumor tissues. Our anti-CA9 products are subjected to comprehensive testing and validation processes to guarantee their superior quality and dependability. This commitment to excellence empowers researchers to conduct critical studies with confidence.
CA9, or Carbonic Anhydrase IX, is primarily located in the gastrointestinal system, where it plays an essential role in the regulation of acid production. This transmembrane glycoprotein features an active site located extracellularly and is classified as a tumor-associated isoenzyme of carbonic anhydrase. Research has shown that CA9 is significantly over-expressed in clear cell renal cell carcinoma (ccRCC) associated with VHL mutations, as well as in various hypoxic solid tumors. Due to its minimal presence in normal tissues combined with its heightened expression in numerous cancer types, CA9 has emerged as an attractive target for therapeutic interventions.
Carbonic anhydrase 9; Carbonic anhydrase IX; CAIX; MN
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide. They participate in a variety of biological processes, including respiration, calcification, acid-base balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, and gastric acid. They show extensive diversity in tissue distribution and in their subcellular localization. CA IX is a transmembrane protein and is one of only two tumor-associated carbonic anhydrase isoenzymes known. It is expressed in all clear-cell renal cell carcinoma, but is not detected in normal kidneys or most other normal tissues. It may be involved in cell proliferation and transformation.
Creative Biolabs presents an extensive range of recombinant antibodies targeting CA9, engineered for optimal efficacy in research applications. These antibodies are crafted for high specificity and binding affinity, enabling reliable inhibition of CA9 activity. Moreover, we offer diverse antibody formats to meet various immunological investigations, empowering researchers to advance projects with efficacy and accuracy.
Table 1. Featured anti-CA9 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-0784-CN | Human Anti-CA9 Recombinant Antibody (clone G37) | Human | Human IgG | FC, ELISA, Inhib, FuncS, Cyt, BI, IHC |
TAB-1458CL | Anti-Human CA9 Recombinant Antibody (MSC3) | Human, Mouse | Human IgG1 | FC |
PABZ-017 | Mouse Anti-CA9 Recombinant Antibody (clone M75) | Human | Mouse IgG2b | WB, FuncS |
TAB-707 | Anti-CAIX/CA9 Recombinant Antibody (Girentuximab) | Human | Mouse IgG1 - kappa | WB, FuncS, IF, Neut, ELISA, FC, IP, PK, IHC, Activ |
HPAB-0104-LSX | Human Anti-CA9 Recombinant Antibody | Human | Human IgG | ELISA, FC, Inhib |
Creative Biolabs is committed to delivering top-tier anti-CA9 recombinant antibodies, tailored for breakthroughs in immunological research. Our state-of-the-art laboratories employ rigorous quality control measures to ensure that each antibody exhibits outstanding specificity and efficacy. Furthermore, with a focus on continuous improvement, our expert team diligently enhances our production techniques, ensuring that our offerings remain at the forefront of biotechnological advancements.
Fig.1 WB analysis of anti-CA9 antibody
(Cat# PABZ-017, Creative Biolabs).
Fig.2 ELISA analysis of anti-CA9 antibody
(Cat# PABZ-017, Creative Biolabs).
Fig.3 Dot Blot analysis of anti-CA9 antibody.
(Cat# PABZ-017, Creative Biolabs).
Fig.4 Dot Blot analysis of anti-CA9 antibody.
(Cat# TAB-707, Creative Biolabs).
Fig.5 SEC-HPLC analysis of anti-CA9 antibody
(Cat# TAB-1458CL, Creative Biolabs).
Fig.6 ELISA analysis of anti-CA9 antibody
(Cat# TAB-1458CL, Creative Biolabs).
Our proprietary anti-CA9 recombinant antibody platform utilizes genetically engineered cells to produce high-quality, CA9-specific antibodies. This advanced system enables scalable and efficient manufacturing, ensuring a reliable supply for diverse uses.
Featured Anti-CA9 Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-CA9 recombinant antibody production.
Fig.8 Gram-scale anti-CA9 recombinant antibody production.
Creative Biolabs delivers a wide range of high-quality anti-CA9 recombinant antibodies available in various formats to suit your specific research needs.
Fig.9 Full-length anti-CA9 recombinant antibody production and modalities.
Table 2. Public drug targeting CA9.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
Pre-Registered | Anti-CA9 (Carbonic Anhydrase IX) |
Chimeric Monoclonal Antibodies Nuclear Imaging Agents Radioimmunoconjugates Radiopharmaceuticals Zirconium Complexes |
Cancer Cancer, bladder (urothelial carcinoma) Cancer, kidney (renal cell carcinoma, clear cell) Cancer, solid tumor Triple negative breast cancer |
Heidelberg Pharma (Originator) Memorial Sloan-Kettering Cancer Center Radboud Universiteit Nijmegen Telix Pharmaceuticals Wilex (Heidelberg Pharma) |
Phase I | Anti-CA9 (Carbonic Anhydrase IX) |
Cancer Immunotherapy Chimeric Monoclonal Antibodies Radioimmunoconjugates Radionuclide Therapy Radiopharmaceuticals Yttrium Complexes |
Cancer, kidney Cancer, kidney, metastatic |
Ludwig Institute for Cancer Research Memorial Sloan-Kettering Cancer Center Radboud Universiteit Nijmegen |
Preclinical | Anti-CA9 (Carbonic Anhydrase IX) |
Cancer Immunotherapy Chimeric Monoclonal Antibodies Nuclear Imaging Agents Radioimmunoconjugates Radiopharmaceuticals Zirconium Complexes |
Cancer, colorectal | Provincial Health Services Authority (Originator) |
Preclinical |
Anti-CA9 (Carbonic Anhydrase IX) Anti-CD3 (T-Cell Surface Glycoprotein CD3) Signal Transduction Modulators T-Cell Engagers |
Adoptive Cell Therapy Bispecific Antibody Fusions Cancer Immunotherapy Single-Chain V-Domain Antibody Fragment (scFv) Single-Domain Antibodies |
Cancer | Biotheus (Originator) |
Preclinical |
Antimitotic Drugs Carbonic Anhydrase Type IX Inhibitors Microtubule Destabilizers (Tubulin Polymerization Inhibitors) |
Auristatins Peptide-Drug Conjugates Polypeptides, from 10 AA to 40 AA Site-Specific Drug Delivery |
Cancer |
ETH Zuerich (Originator) Philochem |
Preclinical | Anti-CA9 (Carbonic Anhydrase IX) |
Cancer Immunotherapy Chimeric Monoclonal Antibodies |
Cancer, kidney (renal cell carcinoma) | Kyowa Kirin (Originator) |
Preclinical | Carbonic Anhydrase Type IX Inhibitors |
Indium Complexes Nuclear Imaging Agents Oligopeptides, less than 10 AA Peptide-Drug Conjugates Radiopharmaceuticals |
Cancer | Johns Hopkins University School Medicine (Originator) |
Preclinical | Anti-CA9 (Carbonic Anhydrase IX) |
Antibodies Cancer Immunotherapy |
Cancer |
Checkpoint Therapeutics Dana-Farber Cancer Institute (Originator) |
Preclinical |
Fusion Proteins Polypeptides, from 41 AA |
Cancer Cancer, kidney |
Dendreon Pharmaceuticals (Originator) | |
Biological Testing | Anti-CA9 (Carbonic Anhydrase IX) |
Cancer Immunotherapy Murine Monoclonal Antibodies |
Cancer, kidney | Guangzhou Tongqi Technology (Originator) |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
If you're in search of a trustworthy and high-performance anti-CA9 antibody, look no further. Reach out to us today to tailor a solution that meets your unique requirements.